Sumitomo Mitsui DS Asset Management Company Ltd Sells 21,624 Shares of Bristol Myers Squibb Company $BMY

Sumitomo Mitsui DS Asset Management Company Ltd lowered its stake in Bristol Myers Squibb Company (NYSE:BMY) by 6.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 292,196 shares of the biopharmaceutical company’s stock after selling 21,624 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Bristol Myers Squibb were worth $18,233,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Primecap Management Co. CA acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $1,436,115,000. Legal & General Group Plc acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth approximately $980,862,000. BlackRock Inc. lifted its holdings in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp boosted its position in Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares during the period. Finally, Caisse de depot et placement du Quebec bought a new stake in Bristol Myers Squibb during the second quarter worth approximately $243,646,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: RBC expects Bristol Myers Squibb to exceed third-quarter revenue estimates, reinforcing optimism ahead of the company’s earnings report. RBC expects a third-quarter revenue beat for Bristol Myers Squibb stock
• Positive Sentiment: Bristol Myers Squibb is scheduled to present new oncology data at ESMO 2026, including results for pumitamig, izalontamab brengitecan (iza-bren), and the Opdivo-Yervoy combination. Positive data could support the company’s pipeline and long-term growth outlook. Bristol Myers Squibb Heads To ESMO 2026 With New Oncology Data
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, substantial free-cash-flow generation, and dividend yield of approximately 4.3%. Goldman Sachs also upgraded the stock, adding to bullish sentiment. Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb Upgraded at The Goldman Sachs Group
• Neutral Sentiment: Investor attention across the pharmaceutical sector is elevated ahead of cancer-drug presentations, with Moderna also attracting buying interest. That broader oncology focus may be helping sentiment toward BMY, although the Moderna catalyst is not directly related to Bristol Myers Squibb. Moderna Jumps While Melanoma Vaccine Data Looms
• Negative Sentiment: The company still faces the challenge of replacing revenue from aging blockbuster medicines. Upcoming ESMO results could either validate its pipeline strategy or increase concerns about future growth. Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Guggenheim reiterated a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $71.00 to $66.00 in a research note on Friday, October 9th. Zacks Research raised shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 23rd. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Finally, Wells Fargo & Company lowered their target price on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 13th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.88.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $61.76 on Wednesday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a market capitalization of $126.15 billion, a PE ratio of 13.60, a P/E/G ratio of 0.29 and a beta of 0.19. The stock has a 50-day simple moving average of $63.39 and a 200 day simple moving average of $60.28.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.77 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.